<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(1)</volume><submitter>Weisinger J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite improvement in acute care of immune-mediated thrombotic thrombocytopenic purpura (iTTP), numerous studies showed that patients with iTTP have inferior mental health and health-related quality of life (HRQoL). Caplacizumab led to shorter hospitalization, less plasma exchange, and improved survival in iTTP and might influence long-term HRQoL.&lt;h4>Objectives&lt;/h4>We aimed to address the impact of iTTP on HRQoL, posttraumatic stress disease, depression, and anxiety, as well as the possible role of caplacizumab on improving these features.&lt;h4>Methods&lt;/h4>We conducted a survey among patients with iTTP enrolled in the French thrombotic microangiopathy registry: patients completed the Short Form (SF)-36 HRQoL, the Hospital Anxiety and Depression Scale screening for anxiety</pubmed_abstract><journal>Research and practice in thrombosis and haemostasis</journal><pagination>103297</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804100</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab era.</pubmed_title><pmcid>PMC12804100</pmcid><pubmed_authors>Azoulay E</pubmed_authors><pubmed_authors>Augusto JF</pubmed_authors><pubmed_authors>Choukroun G</pubmed_authors><pubmed_authors>Joly B</pubmed_authors><pubmed_authors>Jaccard A</pubmed_authors><pubmed_authors>Moranne O</pubmed_authors><pubmed_authors>Poullin P</pubmed_authors><pubmed_authors>Weisinger J</pubmed_authors><pubmed_authors>Veyradier A</pubmed_authors><pubmed_authors>Papo T</pubmed_authors><pubmed_authors>Presne C</pubmed_authors><pubmed_authors>Bouzid R</pubmed_authors><pubmed_authors>Fadlallah J</pubmed_authors><pubmed_authors>Cartery C</pubmed_authors><pubmed_authors>Lievre L</pubmed_authors><pubmed_authors>Coppo P</pubmed_authors><pubmed_authors>Tites C</pubmed_authors><pubmed_authors>Benhamou Y</pubmed_authors><pubmed_authors>Baba A</pubmed_authors><pubmed_authors>Gilardin L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab era.</name><description>&lt;h4>Background&lt;/h4>Despite improvement in acute care of immune-mediated thrombotic thrombocytopenic purpura (iTTP), numerous studies showed that patients with iTTP have inferior mental health and health-related quality of life (HRQoL). Caplacizumab led to shorter hospitalization, less plasma exchange, and improved survival in iTTP and might influence long-term HRQoL.&lt;h4>Objectives&lt;/h4>We aimed to address the impact of iTTP on HRQoL, posttraumatic stress disease, depression, and anxiety, as well as the possible role of caplacizumab on improving these features.&lt;h4>Methods&lt;/h4>We conducted a survey among patients with iTTP enrolled in the French thrombotic microangiopathy registry: patients completed the Short Form (SF)-36 HRQoL, the Hospital Anxiety and Depression Scale screening for anxiety</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-10T05:15:11.792Z</modification><creation>2026-06-10T03:07:29.693Z</creation></dates><accession>S-EPMC12804100</accession><cross_references><pubmed>41552747</pubmed><doi>10.1016/j.rpth.2025.103297</doi></cross_references></HashMap>